2022-RA-1304-ESGO Molecular testing of endometrial carcinoma brings growing opportunity to identify patients with inherited risk of cancer

BEDNAŘÍKOVÁ, Markéta, Jitka HAUSNEROVÁ, Luboš MINÁŘ, Jakub TRIZULJAK, Ivona BLAHÁKOVÁ, Lucie EHRLICHOVÁ, Petra VINKLEROVÁ, Michal FELSINGER, Květoslava MATULOVÁ, Petra OVESNÁ and Vít WEINBERGER. 2022-RA-1304-ESGO Molecular testing of endometrial carcinoma brings growing opportunity to identify patients with inherited risk of cancer. In ESGO 2022 Congress. 2022. ISSN 1525-1438. Available from: https://dx.doi.org/10.1136/ijgc-2022-ESGO.303.

Basic information

• Original name: 2022-RA-1304-ESGO Molecular testing of endometrial carcinoma brings growing opportunity to identify patients with inherited risk of cancer
• Authors: BEDNAŘÍKOVÁ, Markéta, Jitka HAUSNEROVÁ, Luboš MINÁŘ, Jakub TRIZULJAK, Ivona BLAHÁKOVÁ, Lucie EHRLICHOVÁ, Petra VINKLEROVÁ, Michal FELSINGER, Květoslava MATULOVÁ, Petra OVESNÁ and Vít WEINBERGER.
• Edition: ESGO 2022 Congress, 2022.

Other information

• Type of outcome: Conference abstract
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 4.800
• Organization unit: Faculty of Medicine
• ISSN: 1525-1438
• Doi: http://dx.doi.org/10.1136/ijgc-2022-ESGO.303

Abstract

Introduction/Background Routine examination of mismatch repair (MMR) status as a part of recently introduced molecular testing in patients with newly diagnosed endometrial carcinoma (EC) enables to identify those with MMR-d (deficient) tumors, the feature known to be associated with Lynch syndrome (LS). We aimed to evaluate the outcomes of genetic testing recommended to EC patients based on results of both tumor molecular testing and clinical examination. Methodology According to the local guidelines, all newly diagnosed EC are tested for MMR-status from January 2021 in University Hospital Brno. Those EC patients with MMR-d tumors or high-risk family or personal history of cancer are referred to genetic counseling. All consecutive primary EC patients diagnosed between January 2021 and April 2022 with known MMR status were identified from the clinical database and checked for results of genetic consulting. Results So far, a total of 109 patients have been involved with median age 64.5 years (30–85), of which 80 (73.4%) with MMR-proficient and 29 (26.6%) MMR-d tumors. Genetic counselling was recommended to 33 (30.2%) patients and performed in 27 (81.8%) patients. At the time of analysis, the results were available in 21 (78%) cases with following outcomes: 2 (9.5%) patients with pathogenic mutations in genes associated with LS, 1 (4.8%) patient with mutation in other gene associated with increased risk of cancer, 1 (4.8%) patient with mutation in gene not related to cancer, 5 (23.8%) patients with variant of unknown significance (VUS) in genes associated with LS, 2 (9.5%) patients with VUS in other genes and 10 (47.6%) patients with negative findings. Conclusion The genetic testing recommended to all newly diagnosed EC patients with MMR-d tumors and/or high-risk family or personal history of cancer resulted in identification of 14.3% patients with hereditary form of cancer in this pilot study.